<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04584190</url>
  </required_header>
  <id_info>
    <org_study_id>RECHMPL19_0327</org_study_id>
    <nct_id>NCT04584190</nct_id>
  </id_info>
  <brief_title>Real Life Use of Omalizumab in Chronic Urticaria</brief_title>
  <acronym>XO-DS</acronym>
  <official_title>Drug Survival of Omalizumab in Chronic Urticaria : a Retrospective Multicentric Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Montpellier</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Lyon Civil Hospitals - Lyon Sud Hospital Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tenon Hospital, Paris</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Nantes University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Grenoble</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Rouen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Lille University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Bordeaux</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre Hospitalier Universitaire de Saint Etienne</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Montpellier</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Chronic urticaria affects up to 1% of the population. Chronic urticaria refractory to&#xD;
      updosing antihistamines can benefit from OMALIZUMAB, which is an anti-IgE IgG1 monoclonal&#xD;
      antibody administrated every 4 weeks subcutaneously which represents a cost of nearly&#xD;
      800€/month excluding nurse fees. Efficacy and good tolerance have already been demonstrated&#xD;
      in real-life large cohorts of patients. A 6 months treatment duration is proposed before&#xD;
      evaluating the efficacy and discontinuating the treatment in the absence of adequate&#xD;
      response. Mean duration of chronic urticaria is 3 to 5 years with high standard deviations.&#xD;
      Therefore, optimal duration of treatment with OMALIZUMAB is unknown and discontinuation&#xD;
      modalities differ between physicians.&#xD;
&#xD;
      The aim of this study is to evaluate the mean duration between initiation and first&#xD;
      discontinuation of OMALIZUMAB in patients treated for chronic urticaria and explore the&#xD;
      different factors influencing this duration and its outcome.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Chronic urticaria affects up to 1% of the population. Rarely, chronic urticaria may be&#xD;
      refractory to updosing four-fold antihistamine drugs and then can be improved with&#xD;
      subcutaneous OMALIZUMAB. OMALIZUMAB is available for chronic urticaria since 2015. It is an&#xD;
      IgG1 monoclonal antibody targeting IgE and administrated every 4 weeks which represent a cost&#xD;
      of nearly 800€/month excluding nurse fees. Efficacy and good tolerance have already been&#xD;
      demonstrated in real-life large cohorts of patients. A 6 months treatment duration is&#xD;
      proposed before evaluating the efficacy and discontinuating the treatment in the absence of&#xD;
      adequate response. Mean duration of chronic urticaria is 3 to 5 yearss with high standard&#xD;
      deviations. Therefore, optimal duration of treatment with OMALIZUMAB is unknown and&#xD;
      discontinuation modalities differ between physicians.&#xD;
&#xD;
      The aim of this study is to evaluate the mean duration between initiation and first&#xD;
      discontinuation of OMALIZUMAB in patients treated for chronic urticaria and explore the&#xD;
      different factors influencing this duration and its outcome.&#xD;
&#xD;
      To accomplish this, the investigators will conduct a restrospective analyse of all patients&#xD;
      treated with OMALIZUMAB for chronic urticaria from 2010 to 2020 in the major French hospital&#xD;
      reference centers for chronic urticaria management : Paris, Lyon, Grenoble, Lille, Bordeaux,&#xD;
      Nantes, Rouen, Saint-Etienne, Montpellier.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2020</start_date>
  <completion_date type="Anticipated">December 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>duration between initiation and first discontinuation of OMALIZUMAB</measure>
    <time_frame>1 day</time_frame>
    <description>assessed at the time of inclusion Description: duration between initiation and first discontinuation of OMALIZUMAB</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>predictive factors of duration between initiation and first discontinuation of omalizumab</measure>
    <time_frame>1 day</time_frame>
    <description>predictive factors of duration between initiation and first discontinuation of omalizumab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>efficacy of omalizumab and relapse at discontinuation</measure>
    <time_frame>1 day</time_frame>
    <description>efficacy of omalizumab and relapse at discontinuation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>discontinuation cause</measure>
    <time_frame>1 day</time_frame>
    <description>discontinuation cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>rechallenge with omalizumab and efficacy</measure>
    <time_frame>1 day</time_frame>
    <description>rechallenge with omalizumab and efficacy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>persistance of antihistamine intake at 1year, 2 years and 3 years</measure>
    <time_frame>at 1year, 2years and 3years</time_frame>
    <description>persistance of antihistamine intake at 1year, 2 years and 3 years</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mid and long-term tolerance of omalizumab.</measure>
    <time_frame>1 day</time_frame>
    <description>mid and long-term tolerance of omalizumab.</description>
  </secondary_outcome>
  <enrollment type="Anticipated">700</enrollment>
  <condition>Chronic Urticaria</condition>
  <eligibility>
    <study_pop>
      <textblock>
        French referal hospital centers of chronic urticaria managment&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  chronic spontaneous or inducible urticaria&#xD;
&#xD;
          -  treated with omalizumab&#xD;
&#xD;
          -  at least once between January the 1st 2010 and july 2020.&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  unknown intiation and discontinuation date of omalizumab&#xD;
&#xD;
          -  omalizumab initiated for asthma&#xD;
&#xD;
          -  other diagnosis (vascularitis, aquagenic pruritus)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Aurélie Du Thanh, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospitals of Montpellier</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Julie Litovsky, resident</last_name>
    <phone>606934527</phone>
    <phone_ext>33</phone_ext>
    <email>julie.litovsky@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Aurélie Du Thanh, MD, PhD</last_name>
    <phone>61148890</phone>
    <phone_ext>33</phone_ext>
    <email>a-du_thanh@chu-montpellier.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Uh Montpellier</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aurélie Du-Thanh, MD, PhD</last_name>
      <phone>467336906</phone>
      <phone_ext>33</phone_ext>
      <email>a-du_thanh@chu-montpellier.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>October 6, 2020</study_first_submitted>
  <study_first_submitted_qc>October 6, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 12, 2020</study_first_posted>
  <last_update_submitted>October 6, 2020</last_update_submitted>
  <last_update_submitted_qc>October 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic urticaria treated with OMALIZUMAB</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urticaria</mesh_term>
    <mesh_term>Chronic Urticaria</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>NC</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

